Acacia Pharma Ltd., of Cambridge, UK, said its phase II study of APD403 to prevent chemotherapy-induced nausea and vomiting (CINV) demonstrated superior results compared to placebo at preventing delayed CINV (the period 24-120 hours following administration of chemotherapy), with the optimal dose improving complete response rate by 26 percent (p = 0.002) and significantly (p <0.05) reducing the incidence of both nausea and vomiting, compared to placebo. Read More
strong>Soricimed Biopharma Inc., of Toronto, presented a poster at PEGS, a protein engineering summit in Boston, showing that SOR-C13, a cancer peptide therapeutic targeting the TRPV6 oncochannel, showed efficacy in breast and ovarian cancer xenografts in a murine model. Read More
Describing the Independent Payment Advisory Board (IPAB) as a threat to patient access to Medicare, 500 national and state-based health care organizations called on Congress to do away with the board that was created under the Affordable Care Act to cut Medicare expenditures. Read More
Trimel Pharmaceuticals Corp., of Toronto, reported first quarter 2015 revenues of $3.2 million from sales of Estrace (estradiol vaginal cream) in Canada, the sale of Natesto (testosterone nasal gel) inventory to support the U.S. product launch and revenues related to amortization of the $25 million up-front fee from the December 2014 licensing deal with Endo International plc, of Dublin, for exclusive marketing rights to Natesto in the U.S. and Mexico. Read More
Cel-Sci Corp., of Vienna, Va., said it launched a public offering of $35 million of common stock, with an option allowing underwriters to purchase up to an additional $5.25 million. Read More
Juno Therapeutics Inc. looked down the West Coast to expand the potential of its genetically engineered T-cell product pipeline, handing a partnership with a small up front but considerable potential to Fate Therapeutics Inc., of San Diego. Read More
DUBLIN – Woodford Patient Capital Trust plc and Malin Corp. plc have co-invested in a $50 million extension to Kymab Ltd.'s series B round, in a transaction that brings two more deep-pocketed investors into the Cambridge, UK-based antibody technology firm. Read More
Researchers have found that the neurodevelopmental disorder Costello syndrome may be due to deregulated signaling to neurons by a supporting cell type, the astrocyte. The findings suggest that modulating the communication between astrocytes and neurons could be an approach to treating the disorder. Read More
The U.S. IPO market continues to generate mixed reviews for biotech this year. As the 16th and 17th IPOs to price on Nasdaq, Colucid Pharmaceuticals Inc. and Adaptimmune Ltd. offered diverging stories, though neither wowed on the first trading day Wednesday. Read More
On the heels of the first sequencing of the human genome, Francis Collins recommended a prospective genetics cohort of patients to provide the foundation for a new approach to health care – precision medicine. Read More
